Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-06688992
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
PF-06688992 is an antibody-drug conjugate (ADC) developed for the treatment of cancer, particularly malignant melanoma. It consists of a monoclonal antibody targeting ganglioside GD3, a surface antigen highly expressed on many malignant melanoma cells. By binding to GD3, the ADC delivers a cytotoxic payload directly to tumor cells, thereby inhibiting their growth and survival. The drug was developed by Pfizer in collaboration with Memorial Sloan-Kettering Cancer Center and has been investigated in clinical trials for unresectable stage III or IV malignant melanoma and multiple myeloma[1][2][5][7].
- Other names
- anti-GD3 antibody-drug conjugate PF-06688992anti-GD-3 antibody-drug conjugate PF-06688992anti-GD 3 antibody-drug conjugate PF-06688992
02
Targets
GD3 (Ganglioside GD3)
Beyond the preview
Go deeper on PF-06688992.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-06688992.